Search Orphan Drug Designations and Approvals
-
Generic Name: | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab |
---|---|
Date Designated: | 07/15/2003 |
Orphan Designation: | For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Cubist Pharmaceuticals 65 Hayden Avenue Lexington, Massachusetts 02421 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-